The Impact of Baseline Risk Factors on the Incidence of Febrile Neutropenia in Breast Cancer Patients Receiving Chemotherapy with Pegfilgrastim Prophylaxis: A Real-World Data Analysis
**Background:** There are sparse data addressing whether standard risk factors for febrile neutropenia (FN) are relevant in patients receiving myelosuppressive chemotherapy and primary prophylaxis for FN, which would have implications for variables to consider during real-world comparative analyses...
Saved in:
Main Authors: | Edward Li, Bridgette Kanz Schroader, David Campbell, Kim Campbell, Weijia Wang |
---|---|
Format: | Article |
Language: | English |
Published: |
Columbia Data Analytics, LLC
2021-06-01
|
Series: | Journal of Health Economics and Outcomes Research |
Online Access: | https://doi.org/10.36469/001c.24564 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Influence of Febrile Neutropenia Period on Plasma Viscosity at Malignancy
by: Ibrahim Tek, et al.
Published: (2013-01-01) -
Evaluating the use of meropenem in hematologic patients with febrile neutropenia
by: R.A. Stuurman, et al.
Published: (2023-10-01) -
Improved Clinical Outcomes with Appropriate Meropenem De-escalation in Patients with Febrile Neutropenia
by: Tyler Luu, et al.
Published: (2024-12-01) -
Clinical Characteristics and Optimization of Empirical Antimicrobial Therapy for Febrile Neutropenia in Patients With Hematologic Malignancies
by: Cui Y, et al.
Published: (2025-02-01) -
Contribution of paranasal sinus, chest, and abdomen/pelvis computed tomography in patients with febrile neutropenia
by: Charles Tran, et al.
Published: (2025-01-01)